Clinical Scorecard: Psilocybin Beats Nicotine Patch in Smoking Trial
At a Glance
| Category | Detail |
|---|---|
| Condition | Tobacco Use Disorder |
| Key Mechanisms | Psilocybin may act through higher-order psychological processes, including changes in self-concept and enhanced psychological flexibility. |
| Target Population | Psychiatrically healthy adult smokers with prior unsuccessful quit attempts. |
| Care Setting | Clinical trial setting at Johns Hopkins Bayview Medical Center. |
Key Highlights
- Psilocybin group had 41% prolonged abstinence at 6 months vs 10% in nicotine patch group.
- More than 6 times the odds of abstinence with psilocybin compared to nicotine patch.
- Secondary outcome showed 52% of psilocybin participants were abstinent vs 25% in nicotine patch group.
- No serious adverse events attributed to either treatment.
- Psilocybin's efficacy aligns with evidence for antiaddiction effects of classic psychedelics.
Guideline-Based Recommendations
Diagnosis
- Assess tobacco use disorder through patient history and prior quit attempts.
Management
- Consider psilocybin combined with cognitive behavioral therapy for smoking cessation.
Monitoring & Follow-up
- Biochemically verify abstinence using exhaled carbon monoxide and urinary cotinine.
Risks
- Monitor for transient elevations in blood pressure and heart rate during psilocybin administration.
Patient & Prescribing Data
82 psychiatrically healthy adult smokers, mean age 47.6 years.
Psilocybin shows promise as a treatment option for tobacco use disorder, warranting further investigation.
Clinical Best Practices
- Utilize a structured cognitive behavioral therapy program alongside pharmacotherapy.
- Ensure thorough monitoring of patients during psilocybin administration.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
